Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer

Journal of the Medical Association of Thailand

Volumn 87, Issue 10, 2004, Pages 1162-1167

  Thongprasert, Sumitra ^a   Chewaskulyong, Busyamas ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Amifostine; Cisplatin toxicity; Lung cancer

Indexed keywords

AMIFOSTINE; CISPLATIN; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG EFFICACY; FATIGUE; FEMALE; FLUSHING; HICCUP; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; SENSORY NEUROPATHY; SIDE EFFECT; SNEEZING; SURVIVAL TIME; THROMBOCYTOPENIA; TINNITUS; TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYTOPROTECTION; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTECTIVE AGENTS; VINBLASTINE;

EID: 8444227474     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. WHO. World health organization mortality statistics. Assessed in June 2000.
2. ChiangMai Cancer Registry. Annual report 1999. Faculty of Medicine, ChiangMai University,Thailand.
3. Ihde DC, Minna JD. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. Curr Probl cancer 1991; 15: 61-104.
4. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung cancer 1999; 24: 17-24
5. Non-small cell lung cancer collaborative group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 331: 899-909.
6. Bunn PA Jr. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin oncol 1989(suppl 6); 16: 10-21.
7. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2- (3-Aminopropylamino)- ethylphosphorothioic acid. Cancer Res 1980; 40: 1519-24.
8. Capizzi RL. The Preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999 (suppl 7); 26: 3-21.
9. Shaw LM, Glover D, Turrisi A, et al. Pharmarcokinetics of WR 2721. Pharmacol Ther 1998; 39: 195-201.
10. Schiller JH, Storer B, Berlin J, et al: Amifostine, cisplatin and vinblastine in metastatic non-small cell lung cancer: A report of high response rates and prolonged surviral. J Clin Oncol 1996; 14: 1913-21.
11. Tannehill SP, Mehta MP, Larson M, et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: Results of a phase II trial. J Clin Oncol 1997; 15: 2850-7.
12. Capizzi RL. Amifostine reduced the incidence of cumulative nephrotoxicity from cisplatin. Laboratory and clinical aspects. Semin Oncol 1999 (suppl 7); 26: 72-81.
13. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide and cisplatin induced toxicities: Results of a randomzed control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12.
14. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-55.
15. Dorr RT and Holmes BC. Dosing considerations with amifostine: A review of the literature and clinical experience. Semin Oncol 1999 (suppl 7); 26: 108-19.
16. Glover DJ, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 1986; 4: 584-8.
17. Glover DJ, Glide JH, Weiler C, et al. WR-2721 and high dose cisplatin. An active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5: 574-8.
18. Wyatt I, Moore RB, Smith LL. Competition of the polyamine uptake into rat lung slices by WR-2721 and analogues. Int J Radiat Biol 1989; 55: 463-72.
19. Smoluk GD, Fahey RC, Calabro-Jones PM, et al. Radioprotection of cells in culture by amifostine and derivatives: Form of the drug responsible for protection. Cancer Res 1988; 48: 3641-7.
20. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): Clinical experiences. Semin Oncol 1994; 21: 8-15.
21. Prager A, Terry NHA, Murray D. Influence of intracellular thiol and polyamin levels on radioprotection by aminothiols. Int J Radiat Biol 1993; 64: 71-81.
22. Savoye C, Swenberg C, Hugot S, et al. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug Ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radist Biol 1997; 2: 193-202.
23. Schimizus, Eguchi Y, Kamike W, et al. Induction of apoptosis as will as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res 1996; 56: 2161-6.
24. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 24:86-107.
25. Romanul F, Bannister RG. Localized area of high alkaline phosphatase activity in endothelium of arteries. Nature 1962; 195: 611-2.
26. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984; 100: 704-13.
27. Alberts DS, Greens, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cylophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-17.
28. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy: risk factors, prognosis and protection by W2721. Cancer 1988;61:2192-5.
29. Avril MF, Ortoli JC, Foriter-Beaulieu M, et al. High dose cisplatin (C) and WR-2721 in metastatic melanoma. Proc Amer Soc Clin Oncol 1982;66:31-5.